Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06281158 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
A Phase 1 study, sponsored by Denali Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT06281158 is a Phase 1 study that has completed, run by Denali Therapeutics. The registered enrollment target is 7 participants.
The verdict
NCT06281158, a Phase 1 study, has completed, sponsored by Denali Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, nonrandomized, single-dose study in healthy male participants to investigate the absorption, metabolism and excretion of DNL343.
Interventions
- DRUG [14C]-DNL343
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2024-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06281158
The ClinicalTrials.gov registry entry for NCT06281158 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denali Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-DNL343 is the first listed.
NCT06281158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06281158 about?
NCT06281158 is a clinical study titled "A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants". This is a Phase 1, open-label, nonrandomized, single-dose study in healthy male participants to investigate the absorption, metabolism and excretion of DNL343.
What is the current status of trial NCT06281158?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2024-03-01. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT06281158?
The interventions under investigation include: [14C]-DNL343 (DRUG).
Who is sponsoring clinical trial NCT06281158?
This trial is sponsored by Denali Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.